中国肿瘤临床与康复

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries[J]. CA Cancer J Clin, 2021. DOI:10.3322/caac.21660.

[2] Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J]. Chin Med J(Engl), 2021, 134(7):783-791. DOI:10.1097/CM9.0000000000001474.

[3] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022:profiles, trends, and determinants[J].Chin Med J(Engl), 2022, 135(5):584-590. DOI:10.1097/CM9.0000000000002108.

[4]石远凯，孙燕，刘彤华.中国恶性淋巴瘤诊疗规范（2015年版）[J].中华肿瘤杂志，2015, 37(2):145-158.

[6]中国抗癌协会淋巴瘤专业委员会，中国医师协会肿瘤医师分会，中国医疗保健国际交流促进会肿瘤内科分会.中国淋巴瘤治疗指南(2021年版)[J].中华肿瘤杂志，2021, 43(7):707-735. DOI:10.3760/cma.j.cn112152-20210516-00382.

[7]国家卫生健康委员会.淋巴瘤诊疗指南（2022年版）[Z].[2022-04-03](2023-01-14). http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74.shtml.

[9]中国临床肿瘤学会.中国临床肿瘤协会（CSCO）淋巴瘤诊疗指南[Z]. http://www.csco.org.cn/cn/index.aspx.(2023-1-14).

[10] Chen H, Zhou Y, Han X, et al. The changing landscape of antilymphoma drug clinical trials in Mainland of China in the past15 years(2005–2020):A systematic review[J]. The Lancet Regional Health–Western Pacific, 2021, 8. DOI:10.1016/j.lanwpc.2021.100097.

[11] Shi Y. Current status and progress of lymphoma management in China[J]. Int J Hematol, 2018, 107(4):405-412. DOI:10.1007/s12185-018-2404-8.

[12] Nguyen-them L, Costopoulos M, Tanguy ML, et al. The CSF IL-10concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients[J]. Eur J Cancer, 2016, 61:69-76.DOI:10.1016/j.ejca.2016.03.080.

[13] Ungureanu A, Le Garff-tavernier M, Costopoulos M, et al. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma[J]. J Neurol,2021, 268(8):2890-2894. DOI:10.1007/s00415-021-10453-5.

[14] Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease:Cotswolds meeting[J]. J Clin Oncol, 1989, 7(11):1630-1636. DOI:10.1200/JCO.1989.7.11.1630.

[15] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification[J]. J Clin Oncol,2014, 32(27):3059-3068. DOI:10.1200/JCO.2013.54.8800.

[16] Rohatiner A, D’amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma[J]. Ann Oncol, 1994, 5(5):397-400.DOI:10.1093/oxfordjournals.annonc.a058869.

[17] Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis[J]. Cancer, 1981, 48(1):198-2 0 6. D OI:10.10 0 2/10 9 7-0142(19810 701)4 8:1<198::a idcncr2820480131>3.0.co;2-v.

[18] Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia[J]. Blood, 1975, 46(2):219-234. DOI:10.1002/ajh.24282.

[19] Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome:a proposal of the International Society for Cutaneous Lymphomas(ISCL)and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer(EORTC)[J]. Blood, 2007, 110(6):1713-1722. DOI:10.1182/blood-2007-03-055749.

[20] Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome:a proposal of the International Society for Cutaneous Lymphomas(ISCL)and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer(EORTC)[J]. Blood, 2007, 110(2):479-484.DOI:10.1182/blood-2006-10-054601.

[21] Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma(RECIL 2017)[J]. Ann Oncol, 2017, 28(7):1436-1447. DOI:10.1093/annonc/mdx097.

[22] Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Lymphoid Neoplasms[J]. Leukemia, 2022, 36(7):1720-1748. DOI:10.1038/s41375-022-01620-2.

[23] Brice P, De kerviler E, Friedberg JW. Classical Hodgkin lymphoma[J]. Lancet, 2021,398(10310):1518-1527. DOI:10.1016/S0140-6736(20)32207-8.

[24]石远凯,陶云霞,何小慧,等.标准治疗模式下霍奇金淋巴瘤患者的生存和预后分析[J].中华医学杂志，2022, 102(41):3295-3303.

[26] Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2005, 23(21):4634-4642.DOI:10.1200/JCO.2005.09.085.

[27] Sasse S, Brockelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma:updated analyses of the german Hodgkin study group HD7, HD8, HD10,and HD11 trials[J]. J Clin Oncol, 2017, 35(18):1999-2007. DOI:10.1200/JCO.2016.70.9410.

[28] Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stageⅠandⅡHodgkin lymphoma:final results of the randomized EORTC/LYSA/FIL H10trial[J]. J Clin Oncol, 2017, 35(16):1786-1794. DOI:doi:10.1200/JCO.2016.68.6394.

[29] Barrington SF, Phillips EH, Counsell N, et al. Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study[J]. J Clin Oncol, 2019, 37(20):1732-1741.DOI:10.1200/JCO.18.01799.

[30] Fuchs M, Goergen H, Kobe C, et al. Positron emission tomographyguided treatment in early-stage favorable Hodgkin lymphoma:final results of the international, randomized phaseⅢHD16 trial by the german Hodgkin study group[J]. J Clin Oncol, 2019, 37(31):2835-2845. DOI:10.1200/JCO.19.00964.

[31] Borchmann P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma(GHSG HD17):a multicentre, open-label, randomised, phase 3 trial[J].The Lancet Oncology, 2021, 22(2):223-234. DOI:10.1016/S1470-2045(20)30601-X.

[32] Von Tresckow B, Kreissl S, Goergen H, et al. Intensive treatment strategies in advanced-stage Hodgkin’s lymphoma(HD9 and HD12):analysis of long-term survival in two randomised trials[J].Lancet Haematol, 2018, 5(10):e462-e473. DOI:10.1016/S2352-3026(18)30140-6.

[33] Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma(AHL2011):a randomised, multicentre, non-inferiority, phase 3study[J]. The Lancet Oncology, 2019, 20(2):202-215. DOI:10.1016/S1470-2045(18)30784-8.

[34] Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advancedstage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles:long-term results of the GITIL/FIL HD 0607 trial[J]. J Clin Oncol,2018, 36(5):454-462. DOI:10.1016/S1470-2045(18)30784-8.

[35] Zinzani PL, Broccoli A, Gioia DM, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma:final results of the phase ii part of the HD0801study[J]. J Clin Oncol, 2016, 34(12):1376-1385. DOI:10.1200/JCO.2015.63.0699.

[36] Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma(HD18):final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group[J]. Lancet, 2017, 390(10114):2790-2802. DOI:10.1016/S0140-6736(17)32134-7.

[37] Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma[J]. N Engl J Med, 2016, 374(25):2419-2429. DOI:10.1056/NEJMoa1510093.

[38] Straus DJ, Dlugosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stageⅢ/Ⅳclassical Hodgkin lymphoma:3-year update of the ECHELON-1 study[J]. Blood,2020, 135(10):735-742. DOI:10.1182/blood.2019003127.

[39] Advani RH, Horning SJ, Hopper T, et al. Mature results of a phaseⅡstudy of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma[J]. J Clin Oncol, 2014, 32(9):912-918. DOI:10.1200/JCO.2013.53.2069.

[40] Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stageⅠA nodular lymphocytepredominant Hodgkin lymphoma:a report from the German Hodgkin Study Group[J]. Blood, 2011, 118(16):4363-4365. DOI:10.1182/blood-2011-06-361055.

[41] Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy[CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma-an Anglo-French collaborative report[J]. Eur J Cancer,2012, 48(11):1700-1706. DOI:10.1016/j.ejca.2011.10.018.

[42] Cencini E, Fabbri A, Bocchia M. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma[J].Br J Haematol, 2017, 176(5):831-833. DOI:10.1111/bjh.14001.

[43] Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma[J]. Blood, 2017, 130(4):472-477. DOI:10.1182/blood-2017-02-766121.

[44] Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression(AETHERA):a randomised, double-blind, placebo-controlled,phase 3 trial[J]. Lancet(London, England), 2015, 385(9980):1853-1862. DOI:10.1016/S0140-6736(15)60165-9.

[45] Voorhees TJ, Beaven AW. Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma[J]. Cancers, 2020, 12(10):2887. DOI:10.3390/cancers12102887.

[46] Ansell SM. Hodgkin lymphoma:2018 update on diagnosis, riskstratification, and management[J]. Am J Hematol, 2018, 93(5):704-715. DOI:10.1002/ajh.25071.

[47] O’connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma:an international, multicentre, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2018, 19(2):257-266.DOI:10.1016/S1470-2045(17)30912-9.

[48] Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma[J]. Blood, 2018, 131(11):1183-1194. DOI:10.1182/blood-2017-10-811224.

[49] Moskowitz AJ, Shah G, Sch?der H, et al. PhaseⅡtrial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma[J]. J Clin Oncol, 2021, 39(28):3109-3117. DOI:10.1200/JCO.21.01056.

[50] Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma:a single centre, phase 1/2 study[J]. Lancet Haematol, 2021, 8(8):e562-e571.DOI:10.1016/S2352-3026(21)00170-8.

[51] Mei MG, Lee HJ, Palmer JM, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE[J]. Blood, 2022, 139(25):3605-3616.DOI:10.1182/blood.2022015423.

[52] Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral m TOR inhibitor everolimus in relapsed Hodgkin lymphoma[J]. Am J Hematol, 2010, 85(5):320-324. DOI:10.1002/ajh.21664.

[53] Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma[J]. Blood, 2011, 118(19):5119-5125. DOI:10.1182/blood-2011-07-362475.

[55] Chen R, Zinzani PL, Fanale MA, et al. PhaseⅡstudy of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma[J]. J Clin Oncol, 2017, 35(19):2125-2132. DOI:10.1200/JCO.2016.72.1316.

[56] Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma(ORIENT-1):a multicentre, single-arm, phase 2 trial[J]. Lancet Haematol, 2019, 6(1):e12-e19. DOI:10.1016/S2352-3026(18)30192-3.

[57] Song Y, Gao Q, Zhang H, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab:results of a phase 2, single-arm, multicenter study[J]. Leukemia,2020, 34(2):533-542. DOI:10.1038/s41375-019-0545-2.

[58] Song Y, Wu J, Chen X, et al. A single-arm, multicenter, phaseⅡstudy of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J]. Clin Cancer Res, 2019, 25(24):7363-7369. DOI:10.1158/1078-0432.CCR-19-1680.

[59] Song Y, Zhou K, Jin C, et al. Penpulimab for relapsed or refractory classical Hodgkin lymphoma:a multicenter, single-arm, pivotal phaseⅠ/Ⅱtrial(AK105-201)[J]. Front Oncol, 2022, 12:925236.DOI:10.3389/fonc.2022.925236.

[60] Lin N, Zhang M, Bai H, et al. Efficacy and safety of GLS-010(zimberelimab)in patients with relapsed or refractory classical Hodgkin lymphoma:A multicenter, single-arm, phaseⅡstudy[J].Eur J Cancer, 2022, 164:117-126. DOI:10.1016/j.ejca.2021.07.021.

[61] Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma(KEYNOTE-204):an interim analysis of a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2021, 22(4):512-524.DOI:10.1016/S1470-2045(21)00005-X.

[62] Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin:a multicentre, multicohort,single-arm phase 2 trial[J]. Lancet Oncol, 2016, 17(9):1283-1294.DOI:10.1016/S1470-2045(16)30167-X.

[63] Moskowitz AJ, Hamlin PA, PERALES MA, et al. PhaseⅡstudy of bendamustine in relapsed and refractory Hodgkin lymphoma[J]. J Clin Oncol, 2013, 31(4):456-460.DOI:10.1200/JCO.2012.45.3308.

[64] Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma[J]. J Clin Oncol, 2019, 37(17):1479-1489. DOI:10.1200/JCO.18.02151.

[65] Liu Y, Wang C, Li X, et al. Improved clinical outcome in a randomized phaseⅡstudy of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma[J]. J Immunother, 2021, 9:e002347. DOI:10.1136/jitc-2021-002347.

[66] Wang C, Liu Y, Dong L, et al. Efficacy of decitabine plus anti-PD-1camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy[J]. Clin Cancer Res,2021, 27(10):2782-2791. DOI:10.1158/1078-0432.CCR-21-0133.

[67] Prusila REI, Haapasaari KM, Marin K, et al. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma[J]. Acta Oncol, 2018, 57(9):1265-1267. DOI:10.1080/0284186X.2018.1450522.

[68] Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease[J]. Ann Oncol, 2002, 13(10):1628-1635. DOI:10.1093/annonc/mdf221.

[69] Hertzberg MS, Crombie C, Benson W, et al. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin’s and Hodgkin’s lymphoma[J]. Ann Oncol, 2006, 17 Suppl 4:iv25-30. DOI:10.1093/annonc/mdj995.

[70] Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine,and vinorelbine:a new induction regimen for refractory and relapsed Hodgkin’s lymphoma[J]. Haematologica, 2007, 92(1):35-41. DOI:10.3324/haematol.10661.

[71] Eichenauer DA, Engert A. How I treat nodular lymphocytepredominant Hodgkin lymphoma[J]. Blood, 2020, 136(26):2987-2993. DOI:10.1182/blood.2019004044.

[72] Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease[J]. N Engl J Med, 1998, 339(21):1506-1514.DOI:10.1056/NEJM199811193392104.

[73] Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US:A longitudinal analysis of the National Cancer Data Base from 1998 to 2011[J]. Am J Hematol, 2015, 90(9):790-795. DOI:10.1002/ajh.24086.

[74] Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China:analysis of 4,638 cases according to the World Health Organization classification[J]. Am J Clin Pathol, 2012, 138(3):429-434. DOI:10.1309/AJCP7YLTQPUSDQ5C.

[75] Shi Y, Han Y, Yang J, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin:Analysis of 1,085 WHO classified cases in a single institution in China[J]. Chin J Cancer Res, 2019, 31(1):152-161. DOI:10.21147/j.issn.1000-9604.2019.01.10.

[77] Rosenwald A, Wright G, Chan W、C, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-Bcell lymphoma[J]. N Engl J Med, 2002, 346(25):1937-1947. DOI:10.1056/NEJMoa012914.

[78] Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004,103(1):275-282. DOI:10.1182/blood-2003-05-1545.

[79] Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J]. J Clin Oncol, 2012, 30(28):3460-3467. DOI:10.1200/JCO.2011.41.4342.

[80] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390. DOI:10.1182/blood-2016-01-643569.

[81] Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications[J]. Cancer Cell, 2020,37(4):551-568. DOI:10.1016/j.ccell.2020.03.015.

[82] International non-Hodgkin’s lymphoma prognostic factors project.A predictive model for aggressive non-Hodgkin’s lymphoma[J]. N Engl J Med, 1993, 329(14):987-994. DOI:10.1056/NEJM199309303291402.

[83] Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index(R-IPI)is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. Blood, 2007, 109(5):1857-1861. DOI:10.1182/blood-2006-08-038257.

[84] Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014, 123(6):837-842. DOI:10.1182/blood-2013-09-524108.

[85] Shi YK, Chen Q, Zhu YZ, et al. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens:a multicenter, randomized, crossover phase 3 study[J]. Anticancer Drugs, 2013, 24(6):641-647. DOI:10.1097/CAD.0b013e3283610b5d.

[86]石远凯,刘鹏,杨晟,等.注射用聚乙二醇化重组人粒细胞集落刺激因子I期临床耐受性试验[J].癌症，2006(4):495-500. DOI:CNKI:SUN:AIZH.0.2006-04-023.

[87]石远凯,何小慧,杨晟,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症的多中心随机对照Ⅱ期临床研究[J].中华医学杂志，2006(48):3414-3419. DOI:CNKI:SUN:ZHYX.0.2006-48-009

[88] Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP[J]. Blood,2012, 119(9):2066-2073. DOI:10.1182/blood-2011-06-359943.

[89] Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis(FLYER):a randomised, phase 3, non-inferiority trial[J]. Lancet,2019, 394(10216):2271-2281. DOI:10.1016/S0140-6736(19)33008-9.

[90] Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma[J]. Blood, 2018, 131(2):174-181. DOI:10.1182/blood-2017-07-793984.

[91] Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma[J]. J Clin Oncol, 2014, 32(11):1112-1118. DOI:10.1200/JCO.2013.51.4505.

[92] Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma:6-year results of an open-label randomised study of the MabThera International Trial(MInT)Group[J]. Lancet Oncol, 2011, 12(11):1013-1022. DOI:10.1016/S1470-2045(11)70235-2.

[93] Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma[J]. New England Journal of Medicine, 2021, 386(4):351-363. DOI:10.1056/NEJMoa2115304.

[94] Thieblemont C, Tilly H, Gomes DA, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J]. J Clin Oncol, 2017, 35(22):2473-2481.DOI:10.1200/JCO.2017.72.6984.

[95] Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen(R-miniCHOP)in elderly patients older than 80 years with diffuse large B-cell lymphoma:a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2011, 12(5):460-468. DOI:10.1016/S1470-2045(11)70069-9.

[98] Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide,vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity:a United Kingdom National Cancer Research Institute trial[J]. J Clin Oncol, 2014, 32(4):282-287. DOI:10.1200/JCO.2013.49.7586.

[99] Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index:a risk model for cns relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. J Clin Oncol, 2016,34(26):3150-3156. DOI:10.1200/JCO.2015.65.6520.

[100] Vitolo U, Chiappella A, Ferreri A J, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximabCHOP, CNS prophylaxis, and contralateral testis irradiation:final results of an international phaseⅡtrial[J]. J Clin Oncol, 2011,29(20):2766-2772. DOI:10.1200/JCO.2010.31.4187.

[101] Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCHrituximab therapy in primary mediastinal B-cell lymphoma[J]. N Engl J Med, 2013, 368(15):1408-1416. DOI:10.1056/NEJMoa1214561.

[103] Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, doseescalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with doublehit lymphomas:a systematic review and meta-analysis[J]. Br J Haematol, 2015, 170(4):504-514. DOI:10.1111/bjh.13463.

[104] Schaff LR, Grommes C. Primary central nervous system lymphoma[J]. Blood, 2022, 140(9):971-979. DOI:10.1002/hon.2598.

[105] Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate,procarbazine, and vincristine followed by consolidation reduceddose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma:final results and long-term outcome[J]. J Clin Oncol, 2013, 31(31):3971-3979. DOI:10.1200/JCO.2013.50.4910.

[106] Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma(G-PCNSL-SG-1):a phase 3, randomised, non-inferiority trial[J]. Lancet Oncol, 2010, 11(11):1036-1047. DOI:10.1016/S1470-2045(10)70229-1.

[107] Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive nonHodgkin’s lymphoma[J]. Cancer Invest, 2006, 24(6):593-600.DOI:10.1080/07357900600814490.

[108] Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone,cytarabine, and oxaliplatin(R-DHAX)is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2010, 10(4):262-269. DOI:10.3816/CLML.2010.n.055.

[109] Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone,cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas:NCIC-CTG LY.12[J]. J Clin Oncol, 2014, 32(31):3490-3496. DOI:10.1200/JCO.2013.53.9593.

[110] Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma[J]. Cancer Chemother Pharmacol, 2009,64(5):907-916. DOI:doi:10.1007/s00280-009-0941-9.

[111] Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma[J].Blood, 2004, 103(10):3684-3688. DOI:10.1182/blood-2003-11-3911.

[112] Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma[J]. N Engl J Med, 1995, 333(23):1540-1545. DOI:10.1056/NEJM199512073332305.

[113] Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1):a single-arm, multicentre, phase 1-2trial[J]. Lancet Oncol, 2019, 20(1):31-42. DOI:10.1016/S1470-2045(18)30864-7.

[114] Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380(1):45-56. DOI:10.1056/NEJMoa1804980.

[115] Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001):a multicentre seamless design study[J]. Lancet, 2020, 396(10254):839-852. DOI:10.1016/S0140-6736(20)31366-0.

[116] Ying Z, Yang H, Guo Y, et al. Relmacabtagene autoleucel(relma-cel)CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China[J]. Cancer Med, 2021,10(3):999-1011. DOI:10.1002/cam4.3686.

[117] Ying Z, Zou D, Yang H, et al. Preliminary efficacy and safety of Relmacabtagene autoleucel(Carteyva)in adults with relapsed/refractory follicular lymphoma in China:A phaseⅠ/Ⅱclinical trial[J]. Am J Hematol, 2022, 97(12):E436-E438. DOI:10.1002/ajh.26711.

[118] Mounier N, EL Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phaseⅡlymphoma study association trial[J]. Haematologica, 2013,98(11):1726-1731. DOI:10.3324/haematol.2013.090597.

[119] Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma:final results from a phase 2randomised study(ROMULUS)[J]. Lancet Haematol, 2019, 6(5):e254-e265. DOI:10.1016/S2352-3026(19)30026-2.

[121] Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas:results of a phaseⅡstudy[J]. Ann Oncol, 2004,15(3):511-516. DOI:10.1093/annonc/mdh093.

[122] Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma:final results of a multicenter phaseⅡstudy[J]. J Clin Oncol, 2016, 34(27):3293-9.DOI:10.1200/JCO.2016.66.4466.

[123] Salles G, Duell J, González barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma(L-MIND):a multicentre, prospective, single-arm, phase 2 study[J]. Lancet Oncol, 2020, 21(7):978-988. DOI:10.1016/S1470-2045(20)30225-4.

[124] Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression[J]. Blood, 2015,125(9):1394-1402. DOI:10.1182/blood-2014-09-598763.

[125] Wang M, Fowler N, Wagner-bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma:a phaseⅡclinical trial[J]. Leukemia, 2013,27(9):1902-1909. DOI:10.1038/leu.2013.95.

[126] Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J]. Nat Med, 2015, 21(8):922-926. DOI:10.1038/nm.3884.

[127] Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma[J]. Ann Hematol, 2014, 93(3):403-409. DOI:10.1007/s00277-013-1879-x.

[128] Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma[J]. J Clin Oncol, 2020, 38(2):155-165. DOI:10.1200/JCO.19.00172.

[129] Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma(LOTIS-2):a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol,2021, 22(6):790-800. DOI:10.1016/S1470-2045(21)00139-X.

[130] Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma(SADAL):a single-arm, multinational, multicentre, open-label, phase 2 trial[J]. Lancet Haematol, 2020, 7(7):e511-e522. DOI:10.1016/S2352-3026(20)30120-4.

[132] Han Xh, Zhang MZ, Wang Huaqing, et al. A multi-center, openlabel, randomized, parallel-controlled phaseⅡstudy comparing pharmacokinetic, pharmacodynamics and safety of ripertamab(SCT400)to rituximab(MabThera?)in patients with CD20-positive B-cell non-Hodgkin lymphoma[J]. Chin J Cancer Res, 2022, 34(6):601-611. DOI:10.21147/j.issn.1000-9604.2022.06.08.

[133] Shi Y, Zhang Q, Hong X, et al. Comparison of efficacy and safety of ripertamab(SCT400)versus rituximab(Mabthera?in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma:A randomized, single-blind, phaseⅢclinical trial[J]. Hematol Oncol, 2022, 40(5):930-940. DOI:10.1002/hon.3054.

[134] Shi Y, Zhang Q, Han X, et al. Phase 1 studies comparing safety,tolerability, pharmacokinetics and pharmacodynamics of HLX01(a rituximab biosimilar)to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma[J]. Chin J Cancer Res, 2021,33(3):405-416. DOI:10.21147/j.issn.1000-9604.2021.03.11.

[135] Shi Y, Song Y, Qin Y, et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma[J]. J Hematol Oncol, 2020, 13(1):38. DOI:10.1186/s13045-020-00871-9.

[136] Song Y, Zhou H, Zhang H, et al. Efficacy and safety of the biosimilar IBI301 plus standard chop(I-CHOP)in comparison with rituximab plus CHOP(R-CHOP)in patients with previously untreated diffuse large b-cell lymphoma(DLBCL):a randomized, double-blind,parallel-group, phase 3 trial[J]. Adv Ther, 2021, 38(4):1889-1903.DOI:10.1007/s12325-020-01603-8.

[137] Jiang B, Ke X, Zhang Q, et al. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+B-cell lymphoma:a multicenter, randomized, double-blind, parallel-controlled study[J].Sci Rep, 2020, 10(1):11676. DOI:10.1038/s41598-020-68360-0.

[139] Wang XM, Bassig BA, Wen JJ, et al. Clinical analysis of 1629 newly diagnosed malignant lymphomas in current residents of Sichuan province, China[J]. Hematol Oncol, 2016, 34(4):193-199. DOI:10.1002/hon.2202.

[140] Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China:analysis of 6,382 cases using WHO classification in a single institution[J]. Diagn Pathol, 2011, 6:77.DOI:10.1186/1746-1596-6-77.

[141] Zhou Y, Qin Y, He X, et al. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era:A China single-center retrospective study[J]. Asia Pac J Clin Oncol,2021, 17(3):289-299. DOI:10.1111/ajco.13463.

[142] Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for StageⅠ-Ⅱfollicular lymphomas[J]. Int J Radiat Oncol Biol Phys, 2001, 51(5):1219-1227. DOI:10.1016/s0360-3016(01)01747-3.

[143] Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma[J]. N Engl J Med, 2017, 377(14):1331-1344. DOI:10.1056/NEJMoa1614598.

[144] Martin P, Jung SH, Pitcher B, et al. A phaseⅡtrial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma(NHL):CALGB 50803(Alliance)[J]. Ann Oncol, 2017,28(11):2806-2812. DOI:10.1093/annonc/mdx496.

[145] Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma[J]. N Engl J Med, 2018, 379(10):934-947. DOI:10.1056/NEJMoa1805104.

[146] Van oers MH, Van glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma:long-term outcome of the EORTC 20981 phaseⅢrandomized intergroup study[J]. J Clin Oncol, 2010, 28(17):2853-2858. DOI:10.1200/JCO.2009.26.5827.

[147] Bachy E, Seymour J F, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma:long-term results of the PRIMA study[J]. J Clin Oncol,2019, 37(31):2815-2824. DOI:10.1200/JCO.19.01073.

[148] H i d d e m a n n W, B a r b u i A M, C a n a l e s M A, e t a l.Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study:influence of chemotherapy on efficacy and safety[J]. J Clin Oncol,2018, 36(23):2395-2404. DOI:10.1200/JCO.2017.76.8960.

[149] Leonard JP, Trneny M, Izutsu K, et al. AUGMENT:A phaseⅢstudy of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma[J]. J Clin Oncol, 2019,37(14):1188-1199. DOI:10.1200/JCO.19.00010.

[150] Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximabrefractory indolent non-Hodgkin lymphoma(GADOLIN):a randomised, controlled, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2016, 17(8):1081-1093. DOI:10.1016/S1470-2045(16)30097-3.

[151] Shi YK, Hong XN, Yang JL, et al. Bendamustine treatment of Ch i nese pat ients with relapsed i ndolent non-Hodg k i n lymphoma:a multicenter, open-label, single-arm, phase 3 study[J]. Chin Med J(Engl), 2021, 134(11):1299-1309. DOI:10.1097/CM9.0000000000001463.

[152] Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma[J]. J Clin Oncol, 2009, 27(32):5404-5409. DOI:10.1200/JCO.2008.21.1169.

[153] Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma:2-year follow-up of the CHRONOS-1study[J]. Am J Hematol, 2020, 95(4):362-371. DOI:10.1002/ajh.25711.

[154] Morschhauser F, Le gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma(GALEN):a multicentre, single-arm, phase 2study[J]. Lancet Haematol, 2019, 6(8):e429-e437. DOI:10.1016/S2352-3026(19)30089-4.

[155] Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma(ZUMA-5):a single-arm, multicentre, phase 2 trial[J]. Lancet Oncol, 2022,23(1):91-103. DOI:10.1016/S1470-2045(21)00591-X.

[156] Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma:the phase 2ELARA trial[J]. Nat Med, 2022, 28(2):325-332. DOI:10.1038/s41591-021-01622-0.

[157] Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma[J]. J Clin Oncol, 2017, 35(35):3898-3905. DOI:10.1200/JCO.2017.75.4648.

[158] Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO:a phase ii study of duvelisib(IPI-145)in patients with refractory indolent nonHodgkin lymphoma[J]. J Clin Oncol, 2019, 37(11):912-922. DOI:10.1200/JCO.18.00915.

[159] Salles G, Schuster S J, De vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab-and alkylating agentrefractory follicular lymphoma:a subgroup analysis of a phase 2study[J]. Haematologica, 2017, 102(4):e156-e159. DOI:10.3324/haematol.2016.151738.

[160] Wang T, Sun X, Qiu L, et al. P1119:The oral Pi3kΔinhibitor linperlisib for the treatment of relapsed or refractory follicular lymphoma:a single-arm multicenter phase 2 clinical trial[J].Hemasphere, 2022, 6(Suppl):1009-1010. DOI:10.1097/01.HS9.0000847344.35314.45. eCollection 2022 Jun.

[161] Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma:an open-label,single-arm, multicentre, phase 2 trial[J]. Lancet Oncol, 2020, 21(11):1433-1442. DOI:10.1016/S1470-2045(20)30441-1.

[162] Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma:a single-arm, multicentre, phase2 study[J]. Lancet Oncol, 2022, 23(8):1055-1065. DOI:10.1016/S1470-2045(22)00335-7.

[163] Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximabrefractory indolent non-Hodgkin lymphoma(GADOLIN):a randomised, controlled, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2016, 17(8):1081-1093. DOI:10.1016/S1470-2045(16)30097-3.

[164] Montoto S, Lopez-guillermo A, Altes A, et al. Predictive value of Follicular Lymphoma International Prognostic Index(FLIPI)in patients with follicular lymphoma at first progression[J]. Ann Oncol, 2004, 15(10):1484-1489. DOI:10.1093/annonc/mdh406.

[165] Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2:a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project[J]. J Clin Oncol, 2009, 27(27):4555-4562. DOI:10.1200/JCO.2008.21.3991.

[166] Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT[J]. Ann Oncol, 2007, 18(2):346-350. DOI:10.1093/annonc/mdl388.

[167] Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles[J]. Cancer, 2004, 100(1):107-115. DOI:10.1002/cncr.11893.

[169] Ruskone-fourmestraux A, Fischbach W, Aleman BM, et al.EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT[J]. Gut, 2011, 60(6):747-758. DOI:10.1136/gut.2010.224949.

[170] Ruskone-fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas[J]. Gut,2003, 52(6):912-913. DOI:10.1136/gut.52.6.912.

[171] Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy[J]. Cancer, 2010, 116(16):3815-3824.DOI:10.1002/cncr.25226.

[172] Teckie S, Qi S, Chelius M, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma[J]. Ann Oncol, 2017, 28(5):1064-1069. DOI:10.1093/annonc/mdx025.

[173] Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy[J]. J Clin Oncol, 2005, 23(9):1979-1983. DOI:10.1200/JCO.2005.08.128.

[174] Vanazzi A, Grana C, Crosta C, et al. Efficacy of 90Yttriumibritumomab tiuxetan in relapsed/refractory extranodal marginalzone lymphoma[J]. Hematol Oncol, 2014, 32(1):10-15. DOI:10.1002/hon.2078.

[175] Panayiotidis P, Follows GA, Mollica L, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma[J]. Blood Adv, 2021, 5(3):823-828. DOI:10.1182/bloodadvances.2020002910.

[176] Noy A, De vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibr utinib in relapsed/refractory marginal zone lymphoma[J]. Blood, 2017, 129(16):2224-2232. DOI:10.1182/blood-2016-10-747345.

[177] Sacchi S, Marcheselli R, Bari A, et al. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma:final results of a phaseⅡstudy conducted by the Fondazione Italiana Linfomi[J]. Haematologica, 2016, 101(5):196-199. DOI:10.3324/haematol.2015.139329.

[179]李小秋,李甘地,高子芬,等.中国淋巴瘤亚型分布:国内多中心性病例10002例分析[J].诊断学理论与实践, 2012, 11(2):111-115.DOI:10.3969/j.issn.1671-2870.2012.02.006

[180] E i c h h o r s t B, Fi n k A M, B a h l o J, e t a l. Fi r s t-l i n e chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia(CLL10):an international,open-label, randomised, phase 3, non-inferiority trial[J]. Lancet Oncol, 2016, 17(7):928-942. DOI:10.1016/S1470-2045(16)30051-1.

[181] Castro JE, James DF, Sandoval-sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia[J]. Leukemia, 2009, 23(10):1779-1789. DOI:10.1038/leu.2009.133.

[183] Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia[J]. N Engl J Med, 2019, 381(5):432-443. DOI:10.1056/NEJMoa1817073.

[184] Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia(iLLUMINATE):a multicentre,randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(1):43-56. DOI:10.1016/S1470-2045(18)30788-5.

[185] Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia:primary analysis results from the minimal residual disease cohort of the randomized phaseⅡcaptivate study[J]. J Clin Oncol, 2021, 39(34):3853-3865. DOI:10.1200/JCO.21.00807.

[186] Al-sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia(CLL14):follow-up results from a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol,2020, 21(9):1188-200. DOI:10.1016/S1470-2045(20)30443-5.

[187] Hallek M, Fischer K, Fingerle-rowson G, et al. Addition of rituximab to f ludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia:a randomised, open-label, phase 3 trial[J]. Lancet, 2010, 376(9747):1164-1174. DOI:10.1016/S0140-6736(10)61381-5.

[188] Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL:5 years of follow-up from the phase 3 RESONATE-2 study[J]. Leukemia,2020, 34(3):787-798. DOI:10.1038/s41375-019-0602-x.

[189] Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med, 2015,373(25):2425-2437. DOI:10.1056/NEJMoa1509388.

[190] Fischer K, Al-sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions[J]. N Engl J Med,2019, 380(23):2225-2236. DOI:10.1056/NEJMoa1815281.

[191] Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia(ELEVATE TN):a randomised, controlled, phase 3 trial[J]. Lancet, 2020, 395(10232):1278-1291. DOI:10.1016/S0140-6736(20)30262-2.

[192] Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma:interim analysis of a randomized phaseⅢtrial[J]. J Clin Oncol, 2022, JCO2200510. DOI:10.1200/JCO.22.00510.

[193] Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma(SEQUOIA):a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(8):1031-1043. DOI:10.1016/S1470-2045(22)00293-5.

[194] Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib:phase 2, single-arm, multicenter study[J]. J Hematol Oncol, 2020, 13(1):48. DOI:10.1186/s13045-020-00884-4.

[196] Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia[J]. N Engl J Med, 2018, 378(12):1107-1120. DOI:10.1056/NEJMoa1713976.

[197] Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2014,370(11):997-1007. DOI:10.1002/ajh.25595.

[198] Osterborg A, Jewell RC, Padmanabhan-iyer S, et al. Ofatumumab monotherapy in f ludarabine-refractory chronic lymphocytic leukemia:final results from a pivotal study[J]. Haematologica, 2015,100(8):311-314. DOI:10.3324/haematol.2014.121459.

[199] Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial:duvelisib vs ofatumumab in relapsed and refractory CLL/SLL[J]. Blood, 2018, 132(23):2446-2455. DOI:10.1182/blood-2018-05-850461.

[200] International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia(CLL-IPI):a meta-analysis of individual patient data[J]. Lancet Oncol, 2016,17(6):779-790. DOI:10.1016/S1470-2045(16)30029-8.

[201]朱华渊,王莉,乔佳,等. CLL-IPI评分系统在中国慢性淋巴细胞白血病患者中的预后评估价值[J].中华血液学杂志, 2018, 39(5):392-397. DOI:10.3760/cma.j.issn.0253-2727.2018.05.009

[202] Thompson M, Brander D, Nabhan C, et al. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents:a review[J]. JAMA Oncol, 2018, 4(3):394-400. DOI:10.1001/jamaoncol.2017.2009.

[203] Wierda WG, Rawstron A, Cymbalista F, et al. Measurable residual disease in chronic lymphocytic leukemia:expert review and consensus recommendations[J]. Leukemia, 2021, 35(11):3059-3072.DOI:10.1038/s41375-021-01241-1.

[204] A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project[J]. Blood, 1997, 89(11):3909-3918.DOI:10.1056/NEJM199309303291402.

[205] Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype:results of the HAEMACARE project[J]. Blood, 2010, 116(19):3724-3734. DOI:10.1182/blood-2010-05-282632.

[206] Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with antiCD20 immunochemotherapy:results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group[J]. Blood, 2008, 111(4):2385-2387. DOI:10.1182/blood-2007-10-117010.

[207] Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy[J]. Blood, 2017, 130(17):1903-1910.DOI:10.1182/blood-2017-04-779736.

[208] Flinn IW, Van der jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP:results of the BRIGHT 5-year follow-up study[J]. J Clin Oncol, 2019, 37(12):984-991. DOI:10.1200/JCO.18.00605.

[209] Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label,multicentre, randomised, phase 3 non-inferiority trial[J]. Lancet,2013, 381(9873):1203-1210. DOI:10.1016/S0140-6736(12)61763-2.

[211] Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma[J]. N Engl J Med, 2015,373(19):1835-1844. DOI:10.1056/NEJMoa1505237.

[212] Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med,2013, 369(6):507-516. DOI:10.1056/NEJMoa1306220.

[213] Li G, Liu X, Chen XY. Simultaneous development of zanubrutinib in the USA and China[J]. 2020, 17(10):589-590. DOI:10.1038/s41571-020-0414-y.

[214] Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton’s tyrosine kinase[J]. Clin Cancer Res, 2020,26(16):4216-4224. DOI:10.1158/1078-0432.CCR-19-3703.

[216] Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma(ACE-LY-004):a single-arm,multicentre, phase 2 trial[J]. Lancet, 2018, 391(10121):659-667.DOI:10.1016/S0140-6736(17)33108-2.

[217] Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med,2020, 382(14):1331-1342. DOI:10.1056/NEJMoa1914347.

[218] Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study[J]. J Clin Oncol, 2022,JCO2102370. DOI:10.1200/JCO.21.02370.

[220] Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index(MIPI)is superior to the International Prognostic Index(IPI)in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation(ASCT)[J]. Blood, 2010, 115(8):1530-1533. DOI:10.1182/blood-2009-08-236570.

[221] Hoster E, Dreyling M, Klapper W, et al. A new prognostic index(MIPI)for patients with advanced-stage mantle cell lymphoma[J].Blood, 2008, 111(2):558-565. DOI:10.1182/blood-2007-06-095331.

[223] Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma[J]. Blood, 2004, 104(10):3009-3020. DOI:10.1182/blood-2004-02-0405.

[224] Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma[J]. N Engl J Med, 2013, 369(20):1915-1925. DOI:10.1056/NEJMoa1308392.

[225] Thomas DA, Faderl S, O’brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia[J]. Cancer,2006, 106(7):1569-1580. DOI:10.1002/cncr.21776.

[227] Chen H, Tao Y, Zhou Y, et al. The clinical features, treatment,and prognostic factors for peripheral T-cell lymphomas:A singleinstitution analysis of 240 Chinese patients[J]. Asia Pac J Clin Oncol, 2022. DOI:10.1111/ajco.13831.

[228] Olszewski AJ, Jakobsen LH, Collins GP, et al. Burkitt lymphoma international prognostic index[J]. J Clin Oncol, 2021, 39(10):1129-1138. DOI:10.1200/JCO.20.03288.

[230] Armitage JO. The aggressive peripheral T-cell lymphomas:2017[J].Am J Hematol, 2017, 92(7):706-715. DOI:10.1002/ajh.24791.

[231] Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25):4124-4130.DOI:10.1200/JCO.2008.16.4558.

[232] Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma[J]. Blood, 2014, 123(19):2915-2923. DOI:10.1182/blood-2013-11-536359.

[233] Corradini P, Vitolo U, Rambaldi A, et al. Intensified chemoimmunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma[J]. Leukemia,2014, 28(9):1885-1891. DOI:10.1038/leu.2014.79.

[234] D’amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma:NLG-T-01[J]. J Clin Oncol, 2012, 30(25):3093-3099. DOI:10.1200/JCO.2011.40.2719.

[235] Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction:an analysis of patients from LYSA centers[J]. Ann Oncol, 2018, 29(3):715-723. DOI:10.1016/j.annonc.2021.04.021.

[236] Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas:results of a prospective multicenter study[J]. J Clin Oncol, 2009,27(1):106-113. DOI:10.1200/JCO.2008.17.4870.

[237] Gui L, Shi YK, He XH, et al. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma:treatment outcome and prognostic factor analysis[J]. Int J Hematol, 2014,99(1):69-78. DOI:10.1007/s12185-013-1465-y.

[238] Zhang XM, Li YX, Wang WH, et al. Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified[J]. Int J Radiat Oncol Biol Phys, 2013, 85(4):1051-1056. DOI:10.1016/j.ijrobp.2012.08.015.

[239] Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma:a multicenter real-world study in China[J]. J Hematol Oncol, 2017, 10(1):69. DOI:10.1186/s13045-017-0439-6.

[240] Shi Y, Dong M, Hong X, et al. Results from a multicenter, openlabel, pivotal phaseⅡstudy of chidamide in relapsed or refractory peripheral T-cell lymphoma[J]. Ann Oncol, 2015, 26(8):1766-1771.DOI:10.1093/annonc/mdv237.

[241] O’connor OA, Horwitz S, Masszi T, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma:Results of the Pivotal PhaseⅡBELIEF(CLN-19)Study[J]. J Clin Oncol, 2015,33(23):2492-2499. DOI:10.1200/JCO.2014.59.2782.

[242] Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, openlabel, phaseⅡstudy of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy[J]. J Clin Oncol, 2012, 30(6):631-636. DOI:10.1200/JCO.2011.37.4223.

[243] Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma:pivotal study update demonstrates durable responses[J]. J Hematol Oncol, 2014, 7:11. DOI:10.1186/1756-8722-7-11.

[244] O’connor OA, Pro B, Pinter-brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma:results from the pivotal PROPEL study[J]. J Clin Oncol, 2011, 29(9):1182-1189.DOI:10.1200/JCO.2010.29.9024.

[246] Gambacorti PC, Farina F, Stasia A, et al. Crizotinib in advanced,chemoresistant anaplastic lymphoma kinase-positive lymphoma patients[J]. J Natl Cancer Inst, 2014, 106(2):djt378. DOI:10.1093/jnci/djt378.

[247] Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients:evaluation of the longterm outcome[J]. Ann Oncol, 2010, 21(4):860-863. DOI:10.1093/annonc/mdp508.

[248] Shi Y, Wu J, Wang Z, et al. Efficacy and safety of geptanolimab(GB226)for relapsed or refractory peripheral T cell lymphoma:an open-label phase 2 study(Gxplore-002)[J]. J Hematol Oncol, 2021,14(1):12. DOI:10.1186/s13045-021-01033-1.

[249] Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phaseⅡtrial of bendamustine in refractory or relapsed T-cell lymphomas:the BENTLY trial[J]. J Clin Oncol,2013, 31(1):104-110. DOI:10.1200/JCO.2012.43.7285.

[250] Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma[J]. Cancer, 2015, 121(5):716-723. DOI:10.1002/cncr.29103.

[251] Zinzani PL, Musuraca G, Tani M, et al. PhaseⅡtrial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2007, 25(27):4293-4297. DOI:10.1200/JCO.2007.11.4207.

[254] Velasquez WS, Mclaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma:a4-year follow-up study[J]. J Clin Oncol, 1994, 12(6):1169-1176.DOI:10.1200/JCO.1994.12.6.1169.

[256] Park BB, Kim WS, Suh C, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin(GDP)for patients with relapsed or refractory peripheral T-cell lymphomas:a consortium for improving survival of lymphoma(CISL)trial[J]. Ann Hematol,2015, 94(11):1845-1851. DOI:10.1007/s00277-015-2468-y.

[257] Qian Z, Song Z, Zhang H, et al. Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma[J]. Biomed Res Int, 2015, 2015:606752. DOI:10.1155/2015/606752.

[259] Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma:a multicenter real-world study in China[J]. J Hematol Oncol,2017,10(1):69. DOI:10.1186/s13045-017-0439-6.

[260] Hong X, Song Y, Huang H, et al. Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma:a singlearm, multicenter study[J]. Target Oncol, 2019, 14(2):149-158. DOI:10.1007/s11523-019-00630-y.

[261] Yang J, Shi Y, Li C, et al. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s:pharmacokinetics, toxicity and preliminary efficacy[J]. Cancer Chemother Pharmacol, 2014, 74(3):637-646.DOI:10.1007/s00280-014-2523-8.

[263] Jia B, Hu S, Yang J, et al. Comparison of gemcitabin, cisplatin, and dexamethasone(GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas[J]. Hematology, 2016, 21(9):536-541. DOI:10.1080/10245332.2016.1152084.

[264] Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified(PTCL-U):a new prognostic model from a retrospective multicentric clinical study[J]. Blood, 2004, 103(7):2474-2479.DOI:10.1182/blood-2003-09-3080.

[265] Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:a study of 136 cases from the International Peripheral T-Cell Lymphoma Project[J]. Blood, 2009, 113(17):3931-3937.DOI:10.1182/blood-2008-10-185256.

[266] Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma,nasal-type in the upper aerodigestive tract[J]. Int J Radiat Oncol Biol Phys, 2008, 70(1):166-174. DOI:10.1016/j.ijrobp.2007.05.073.

[267] Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:an updated analysis of the Japan clinical oncology group study JCOG0211[J]. J Clin Oncol, 2012, 30(32):4044-4046. DOI:10.1200/JCO.2012.45.6541.

[268] Kim SJ, Kim K, Kim BS, et al. PhaseⅡtrial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stageⅠE toⅡE, nasal, extranodal NK/T-Cell Lymphoma:Consortium for Improving Survival of Lymphoma study[J]. J Clin Oncol, 2009, 27(35):6027-6032. DOI:10.1200/JCO.2009.23.8592.

[269] Wang L, Wang ZH, Chen XQ, et al. First-line combination of GELOX followed by radiation therapy for patients with stageⅠE/ⅡE ENKTL:An updated analysis with long-term follow-up[J]. Oncol Lett, 2015, 10(2):1036-1040. DOI:10.3892/ol.2015.3327.

[270] Zhang L, Jiang M, Xie L, et al. Five-year analysis from phase 2 trial of “sandwich” chemoradiotherapy in newly diagnosed, stageⅠE toⅡE, nasal type, extranodal natural killer/T-cell lymphoma[J].Cancer Med, 2016, 5(1):33-40. DOI:10.1002/cam4.569.

[271] Zhang Y, Ma S, Cai J, et al. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma:A multicenter study[J]. Am J Hematol, 2021, 96(11):1481-1490. DOI:10.1002/ajh.26335.

[273] Wang JH, Wang H, Wang YJ, et al. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma[J]. Oncotarget, 2016, 7(23):35412-35422. DOI:10.18632/oncotarget.8643.

[274] Yamaguchi M, Kwong YL, Kim WS, et al. PhaseⅡstudy of SMILE chemotherapy for newly diagnosed stageⅣ, relapsed, or refractory extranodal natural killer(NK)/T-cell lymphoma, nasal type:the NKCell Tumor Study Group study[J]. J Clin Oncol, 2011, 29(33):4410-4416. DOI:10.1200/JCO.2011.35.6287.

[275] Cai J, Liu P, Huang H, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma[J]. Signal Transduct Target Ther, 2020, 5(1):289. DOI:10.1038/s41392-020-00331-3.

[278] Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment:a multicentre, retrospective analysis[J]. Lancet Oncol, 2016, 17(3):389-400. DOI:10.1016/S1470-2045(15)00533-1.

[279] Chen SY, Yang Y, Qi SN, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:indication for prognostication and clinical decision-making[J]. Leukemia,2021, 35(1):130-142. DOI:10.1038/s41375-020-0791-3.

[280] Sethi TK, Montanari F, Foss F, et al. How we treat advanced stage cutaneous T-cell lymphoma-mycosis fungoides and Sezary syndrome[J]. Br J Haematol, 2021. DOI:10.1111/bjh.17458.

[281] Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma[J]. J Clin Invest, 2005,115(4):798-812. DOI:10.1172/JCI24826.

[282] Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids[J]. Dermatol Ther, 2003, 16(4):283-287.DOI:10.1111/j.1396-0296.2003.01639.x.

[283] Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma:positive results of a randomized,controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides[J]. JAMA Dermatol, 2013, 149(1):25-32. DOI:10.1001/2013.jamadermatol.541.

[284] Zackheim HS. Topical carmustine(BCNU)in the treatment of mycosis fungoides[J]. Dermatol Ther, 2003, 16(4):299-302. DOI:10.1111/j.1396-0296.2003.01641.x.

[285] Diederen PV, Van weelden H, Sanders CJ, et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides:a retrospective study[J]. J Am Acad Dermatol, 2003, 48(2):215-219.DOI:10.1067/mjd.2003.80.

[286] Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma:results of the phaseⅢclinical trial[J]. J Am Acad Dermatol,2003, 49(5):801-815. DOI:10.1016/s0190-9622(03)01475-0.

[287] Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5%cream[J]. J Am Acad Dermatol, 2005, 52(2):275-280. DOI:10.1016/j.jaad.2004.04.049.

[288] Martinez-gonzalez MC, Verea-hernando MM, Yebra-pimentel MT,et al. Imiquimod in mycosis fungoides[J]. Eur J Dermatol, 2008,18(2):148-152. DOI:10.1684/ejd.2008.0352.

[289] Harrison C, Young J, Navi D, et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):651-657. DOI:10.1016/j.ijrobp.2011.01.023.

[290] Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2007,25(21):3109-3115. DOI:10.1200/JCO.2006.10.2434.

[291] Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2010, 28(29):4485-4491. DOI:10.1200/JCO.2010.28.9066.

[292] Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma:multinational phaseⅡ-Ⅲtrial results[J]. J Clin Oncol,2001, 19(9):2456-2471. DOI:10.1200/JCO.2001.19.9.2456.

[293] Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma(ALCANZA):an international, open-label, randomised, phase3, multicentre trial[J]. Lancet, 2017, 390(10094):555-566. DOI:10.1016/S0140-6736(17)31266-7.

[294] Kim YH, Bagot M, Pinter-brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma(MAVORIC):an international, open-label, randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(9):1192-1204. DOI:10.1016/S1470-2045(18)30379-6.

[295] Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome:a multicenter phaseⅡstudy[J]. J Clin Oncol, 2020, 38(1):20-28.DOI:10.1200/JCO.19.01056.

[296] Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome:effect of specific prognostic markers on survival and development of a prognostic model[J]. J Clin Oncol, 2015, 33(32):3766-3773. DOI:10.1200/JCO.2015.61.7142.

[297]中国抗癌协会淋巴瘤专业委员会,中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会.中国淋巴瘤多学科诊疗模式实施指南[J].中华肿瘤杂志，2021, 43(2):163-166. DOI:10.3760/cma.j.cn112152-20201109-00971.